• Epacadostat (INCB024360) in Immune Modulation Workflows

  2026-06-22

  Epacadostat (INCB024360) enables precise dissection of IDO1-mediated immune evasion and T cell restoration in immuno-oncology research. This article bridges bench protocols with practical troubleshooting, highlighting how metabolic modulation assays and advanced workflow optimization unlock new insights for tumor immune microenvironment studies.

• AI-Driven Discovery of Senolytics: Implications for EGFR/Erb

  2026-06-22

  The referenced study demonstrates that machine learning algorithms can identify new senolytic compounds by leveraging existing heterogeneous screening data, reducing the cost and time of early-stage drug discovery. This approach enables the identification of potent molecules with relevance for both cancer and aging research, providing a methodological blueprint for integrating AI into senescence-targeted therapeutic development.

• 25-Hydroxycholesterol-AMPK Axis Reprograms Tumor Macrophages

  2026-06-21

  Xiao et al. (2024) elucidate how lysosome-accumulated 25-hydroxycholesterol (25HC) activates AMPKα in tumor-associated macrophages (TAMs), leading to STAT6-driven immunosuppressive programming. This mechanistic insight reveals CH25H as an immunometabolic checkpoint and suggests new strategies to modulate the tumor microenvironment for improved anti-tumor immunity.

• Uremic Metabolite Adsorption to Hydroxy-PEO Films: Mechanist

  2026-06-20

  This study investigates how uremic metabolites, including 4-ethylphenyl sulfate, adsorb to hydroxy-terminated polyethylene oxide (PEO–OH) films of varying chain densities. The findings reveal structure- and density-dependent adsorption behaviors, emphasizing the need to consider disease-altered metabolite profiles when designing blood-contacting biomaterials and optimizing renal dysfunction biomarker workflows.

• Imidazoles Inhibit AdhE in Cryptosporidium parvum: Drug Lead

  2026-06-19

  The referenced study demonstrates that antifungal imidazoles act as potent, lower micromolar inhibitors of the bifunctional aldehyde/alcohol dehydrogenase (AdhE) in Cryptosporidium parvum. This finding provides mechanistic groundwork for developing new anti-cryptosporidial therapies and highlights the value of targeted compound screening in neglected parasitic diseases.

• Palmitic acid (Hexadecanoic Acid): Technical Use and Protoco

  2026-06-19

  Palmitic acid (SKU N2456) is a high-purity, well-characterized saturated long-chain fatty acid suitable for research in lipid metabolism, protein palmitoylation, and metabolic disorder pathways. It is not appropriate for workflows requiring aqueous solubility or long-term solution storage, demanding careful reconstitution and immediate use for reproducible results.

• CD44-Driven Copper Accumulation Activates Ly6Chi Macrophages

  2026-06-18

  This study elucidates how CD44 upregulation mediates copper accumulation, triggering Ly6Chi macrophage activation and inflammatory progression in ulcerative colitis (UC). The findings provide mechanistic insight into copper metabolism’s role in UC and highlight methodological advances for quantifying oxidative stress during inflammation.

• Modeling Human Pacemaker Maturation with SAN-Plexus Assemblo

  2026-06-18

  This study establishes the first in vitro human model integrating sinoatrial node (SAN) organoids and cardiac plexus organoids (CGPOs) to recapitulate neuro-cardiac interactions driving pacemaker maturation. By mapping neuron-to-pacemaker signaling via PSAP-GPR37, the work offers a platform for dissecting mechanisms of human pacemaker development and disease.

• PARP1/FAK/COL5A1 Axis Drives EMT in Cholesterol-Resistant Ov

  2026-06-17

  This study uncovers how sustained high cholesterol levels promote tumorigenesis in ovarian cancer cells by activating the PARP1/FAK/COL5A1 axis and enhancing epithelial-mesenchymal transition (EMT). The findings illuminate a mechanistic pathway underlying cholesterol-driven cancer progression and offer new therapeutic targets for addressing resistance in ovarian cancer.

• Leucomycin (Kitasamycin): Advanced Workflows in Translationa

  2026-06-17

  Leucomycin (kitasamycin) stands out for its robust inhibition of bacterial protein synthesis, especially in translational inhibition and resistance mechanism studies. This article delivers actionable protocols, troubleshooting guidance, and comparative insights for optimizing antibacterial research using APExBIO’s high-purity compound.

• PPM-18: Applied iNOS/NF-κB Inhibition in Sepsis Research

  2026-06-16

  PPM-18 enables precise, reproducible NF-κB pathway inhibition for advanced sepsis and inflammation research, outperforming conventional iNOS inhibitors. This guide unpacks practical workflows, troubleshooting, and how PPM-18’s targeted mechanism unlocks new experimental possibilities.

• mCherry mRNA Redefines Reporter Assays for Translational Sci

  2026-06-16

  Explore how next-generation mCherry mRNA reagents, with advanced capping and nucleotide modifications, are revolutionizing reporter gene assays. This thought-leadership article combines mechanistic detail with strategic insights for translational researchers, spotlighting the unique value of EZ Cap™ mCherry mRNA (5mCTP, ψUTP) for robust, reproducible, and immune-evasive fluorescent protein expression.

• Chlorpromazine Hydrochloride: Optimizing Antipsychotic Resea

  2026-06-15

  Chlorpromazine hydrochloride stands at the nexus of antipsychotic and antiemetic research, offering high-purity, reliable performance for dissecting dopamine receptor pathways and cell-based assays. This article spotlights advanced applications, protocol enhancements, and troubleshooting strategies—anchored by recent breakthroughs in hepatic nanoparticle interaction studies.

• NEDD4L Suppresses Colorectal Cancer Metastasis via PRMT5 Deg

  2026-06-15

  This study identifies NEDD4L as a key E3 ubiquitin ligase that prevents colorectal cancer liver metastasis by targeting PRMT5 for degradation, thereby inhibiting the AKT/mTOR pathway. These findings reveal a novel molecular mechanism with potential implications for therapeutic strategies targeting metastatic colorectal cancer.

• MG-132 (Z-LLL-al): Applied Workflows in Cancer and Apoptosis

  2026-06-14

  MG-132 (Z-LLL-al) stands out as a potent, cell-permeable proteasome inhibitor critical for apoptosis, cell cycle, and oxidative stress research. This guide presents optimized workflows, troubleshooting strategies, and actionable protocol parameters that maximize reproducibility and sensitivity in cancer and neurobiology models.

16735 records 1/1116 page Next 12345 下5页 Last page